Table 2.
Comparison between groups across the preoperative variables.
| Category | Variable | Control | Oncoplastic surgery | Total | p |
|---|---|---|---|---|---|
| Age | Media | 48.27 ± DP 1.69 | 49.75 ± DP 1.80 | 48.76 ± DP 1.25 | 0.58 |
| Initial size | Media | 5.25 ± DP 1.52 | 5.26 ± DP 1.66 | 5.25 ± DP 1.56 | 0.97 |
| Period | 2006–2008 | 29 (55.8%) | 12 (46.2%) | 41 (52.6%) | 0.48 |
| 2009–2010 | 23 (44.2%) | 14 (53.8%) | 37 (47.4%) | ||
| Schooling | <11 years | 37 (71.2%) | 17 (65.4%) | 54 (69.2%) | 0.61 |
| ≥11 years | 15 (28.8%) | 9 (34.6%) | 24 (30.8%) | ||
| Side | Right | 28 (53.8%) | 12 (46.2%) | 40 (51.3%) | 0.53 |
| Left | 22 (42.3%) | 14 (53.8%) | 36 (46.2%) | ||
| Bilateral | 0 (3.8%) | 0 | 2 (2.5%) | ||
| EC/TNM | II | 6 (11.5%) | 2 (7.7%) | 8 (10.3%) | 0.71 |
| III | 46 (88.5%) | 24 (92.3%) | 70 (89.7%) | ||
| EC/TNM | IIa | 2 (3.8%) | 1 (3.8%) | 3 (3.8%) | 0.91 |
| IIb | 4 (7.7%) | 1 (3.8%) | 5 (6.4%) | ||
| IIIa | 28 (53.8%) | 16 (61.5%) | 44 (56.4%) | ||
| IIIb | 14 (26.9%) | 7 (26.9%) | 21 (26.9%) | ||
| IIIc | 4 (7.7%) | 1 (3.08%) | 5 (6.4%) | ||
| EC-T/TNM | T2 | 12 (23.1%) | 5 (19.2%) | 7 (21.8%) | 0.90 |
| T3 | 28 (53.8%) | 14 (53.8%) | 42 (53.8%) | ||
| T4 | 12 (23.1%) | 7 (26.9%) | 19 (24.4%) | ||
| EC-N/TNM | N0 | 9 (17.3%) | 5 (19.2%) | 14 (17.9%) | 0.89 |
| N1 | 30 (57.7%) | 16 (61.5%) | 46 (59.0%) | ||
| N2 + 3 | 13 (25.0%) | 5 (19.2%) | 18 (23.1%) | ||
| Histology | Ductal Invasive | 47 (90.4%) | 24 (92.3%) | 71 (91.0%) | 1.00 |
| Other | 5 (9.6%) | 2 (7.7%) | 7 (9.0%) | ||
| Nuclear grade | G1 | 4 (8.0%) | 2 (7.7%) | 6 (7.9%) | 1.00 |
| G2 + G3 | 46 (92.0%) | 24 (92.3%) | 70 (92.1%) | ||
| Histology grade | G1 | 3 (60.0%) | 1 (3.8%) | 4 (5.3%) | 1.00 |
| G2 + G3 | 47 (94.0%) | 25 (96.2%) | 72 (94.7%) | ||
| RE | Positive | 34 (65.4%) | 14 (53.8%) | 48 (61.5%) | 0.34 |
| Negative | 18 (34.6%) | 12 (46.2%) | 30 (38.5%) | ||
| RP | Positive | 29 (55.8%) | 12 (46.2%) | 41 (52.6%) | 0.48 |
| Negative | 23 (44.2%) | 14 (53.8%) | 37 (47.4%) | ||
| Her2 | Absent | 43 (82.7%) | 17 (65.4%) | 60 (76.9%) | 0.10 |
| Present | 9 (17.3%) | 9 (34.6%) | 18 (23.1%) | ||
| Molecular subtype | Luminal/Her− | 31 (59.6%) | 9 (34.6%) | 40 (51.3%) | 0.08 |
| Luminal/Her+ | 5 (9.6%) | 8 (30.8%) | 13 (16.7%) | ||
| Her + | 4 (7.7%) | 2 (7.7%) | 6 (7.7%) | ||
| Triple negative | 12 (23.1%) | 7 (26.9%) | 19 (24.4%) | ||
| Tumor markup | Absent | 42 (80.8%) | 17 (65.4%) | 59 (75.6%) | 0.17 |
| Present | 10 (19.2%) | 9 (34.6%) | 19 (24.4%) | ||
| Previous radiologic evaluation | MMG | 8 (15.4%) | 2 (7.7%) | 10 (12.8%) | 0.35 |
| MMG + US | 35 (67.3%) | 16 (61.5%) | 51 (65.4%) | ||
| MMG + US + RNM | 9 (17.3%) | 8 (30.8%) | 17 (21.8%) |
MMG = mammography; US = ultrasound; RNM = magnetic resonance; EC = clinical stage.